Singapore markets closed
Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,433.76 +52.41 (+0.63%) Bitcoin USD
60,636.00 -1,765.06 (-2.83%) CMC Crypto 200
1,260.27 -97.74 (-7.19%)
Keros Therapeutics, Inc. (KROS)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 57.60 |
| Open | 58.06 |
| Bid | 54.06 x 100 |
| Ask | 54.46 x 200 |
| Day's range | 53.59 - 58.42 |
| 52-week range | 27.02 - 73.00 |
| Volume | |
| Avg. volume | 347,227 |
| Market cap | 1.958B |
| Beta (5Y monthly) | 1.32 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.15 |
| Earnings date | 05 Aug 2024 - 09 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 90.25 |
GuruFocus.comKeros Therapeutics Reports Widening Losses in Q1 2024, Despite Progress in Clinical Trials
Financial Performance Misses Analyst Forecasts Amid Increased R&D Investments
GlobeNewswireKeros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the quarter ended March 31, 2024. “Keros remaine
Simply Wall St.Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 37%?
Key Insights Keros Therapeutics' estimated fair value is US$93.42 based on 2 Stage Free Cash Flow to Equity Current...
© 2024 Yahoo. All rights reserved.